S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NYSE:BDX

Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

$232.26
+1.25 (+0.54%)
(As of 04/17/2024 ET)
Today's Range
$229.40
$232.63
50-Day Range
$231.01
$247.45
52-Week Range
$229.40
$287.32
Volume
1.51 million shs
Average Volume
1.41 million shs
Market Capitalization
$67.10 billion
P/E Ratio
55.04
Dividend Yield
1.64%
Price Target
$280.00

Becton, Dickinson and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
20.6% Upside
$280.00 Price Target
Short Interest
Healthy
1.02% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.48
Upright™ Environmental Score
News Sentiment
1.03mentions of Becton, Dickinson and Company in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$67,198 Sold Last Quarter
Proj. Earnings Growth
10.66%
From $12.94 to $14.32 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.76 out of 5 stars

Medical Sector

44th out of 914 stocks

Surgical & Medical Instruments Industry

6th out of 94 stocks

BDX stock logo

About Becton, Dickinson and Company Stock (NYSE:BDX)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

BDX Stock Price History

BDX Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Zeus Company, LLC: Zeus Names New Chief Executive Officer
3 Stocks to Buy at 52-Week Lows: March 4 Edition
See More Headlines
Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Becton, Dickinson and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Ex-Dividend for 3/29 Dividend
3/07/2024
Dividend Payable
3/29/2024
Today
4/17/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
07588710
Employees
73,000
Year Founded
1897

Price Target and Rating

Average Stock Price Target
$280.00
High Stock Price Target
$305.00
Low Stock Price Target
$260.00
Potential Upside/Downside
+21.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$1.48 billion
Pretax Margin
7.90%

Debt

Sales & Book Value

Annual Sales
$19.37 billion
Cash Flow
$19.90 per share
Book Value
$88.92 per share

Miscellaneous

Free Float
288,006,000
Market Cap
$66.74 billion
Optionable
Optionable
Beta
0.43

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

  • Becton, Dickinson and Company reported strong quarterly earnings, surpassing analysts' expectations, indicating a healthy financial performance.
  • The company has a diverse product portfolio in medical supplies, devices, laboratory equipment, and diagnostic products, catering to various sectors in the healthcare industry.
  • Institutional investors like Vanguard Group Inc., State Street Corp, and Morgan Stanley have been increasing their stakes in the company, reflecting confidence in its future growth potential.
  • Analysts have issued buy ratings for the stock, with a consensus rating of "Moderate Buy" and an average price target above the current stock price, suggesting potential upside.
  • Becton, Dickinson and Company has a strong market capitalization and a stable financial position, with a reasonable debt-to-equity ratio and healthy liquidity ratios.

Cons

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

  • The stock price has experienced fluctuations, trading below its 200-day moving average, which may indicate short-term volatility or market uncertainty.
  • Despite the positive quarterly earnings, the company's revenue slightly missed analysts' expectations, suggesting potential challenges in revenue growth or market competition.
  • While some analysts have issued buy ratings, there are also hold ratings on the stock, indicating differing opinions on the company's future performance and valuation.
  • The company's beta of 0.42 implies lower volatility compared to the market, which may limit potential returns for investors seeking higher-risk investments.
  • Investors should consider the industry risks associated with healthcare regulations, technological advancements, and competitive pressures that could impact Becton, Dickinson and Company's future prospects.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

BDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Becton, Dickinson and Company stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BDX shares.
View BDX analyst ratings
or view top-rated stocks.

What is Becton, Dickinson and Company's stock price target for 2024?

5 equities research analysts have issued 12 month price objectives for Becton, Dickinson and Company's stock. Their BDX share price targets range from $260.00 to $305.00. On average, they expect the company's stock price to reach $280.00 in the next twelve months. This suggests a possible upside of 20.6% from the stock's current price.
View analysts price targets for BDX
or view top-rated stocks among Wall Street analysts.

How have BDX shares performed in 2024?

Becton, Dickinson and Company's stock was trading at $243.83 at the start of the year. Since then, BDX stock has decreased by 4.7% and is now trading at $232.26.
View the best growth stocks for 2024 here
.

Are investors shorting Becton, Dickinson and Company?

Becton, Dickinson and Company saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,930,000 shares, an increase of 5.0% from the March 15th total of 2,790,000 shares. Based on an average daily volume of 1,430,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.0% of the shares of the company are short sold.
View Becton, Dickinson and Company's Short Interest
.

When is Becton, Dickinson and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BDX earnings forecast
.

How can I listen to Becton, Dickinson and Company's earnings call?

Becton, Dickinson and Company will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Becton, Dickinson and Company's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) announced its quarterly earnings results on Thursday, February, 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping the consensus estimate of $2.39 by $0.29. The medical instruments supplier earned $4.71 billion during the quarter, compared to analysts' expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a trailing twelve-month return on equity of 13.57%. The business's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.98 EPS.
Read the conference call transcript
.

How often does Becton, Dickinson and Company pay dividends? What is the dividend yield for Becton, Dickinson and Company?

Becton, Dickinson and Company declared a quarterly dividend on Tuesday, January 23rd. Investors of record on Friday, March 8th will be given a dividend of $0.95 per share on Friday, March 29th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.64%. The ex-dividend date of this dividend is Thursday, March 7th.
Read our dividend analysis for BDX
.

Is Becton, Dickinson and Company a good dividend stock?

Becton, Dickinson and Company (NYSE:BDX) pays an annual dividend of $3.80 per share and currently has a dividend yield of 1.62%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 90.05%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, BDX will have a dividend payout ratio of 26.54% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BDX.

What guidance has Becton, Dickinson and Company issued on next quarter's earnings?

Becton, Dickinson and Company updated its FY24 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $12.82-13.86 for the period, compared to the consensus EPS estimate of $12.84. The company issued revenue guidance of $20.2-20.4 billion, compared to the consensus revenue estimate of $20.21 billion.

What is Tom Polen's approval rating as Becton, Dickinson and Company's CEO?

136 employees have rated Becton, Dickinson and Company Chief Executive Officer Tom Polen on Glassdoor.com. Tom Polen has an approval rating of 91% among the company's employees. This puts Tom Polen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Becton, Dickinson and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton, Dickinson and Company investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), Walt Disney (DIS), Abbott Laboratories (ABT), Intel (INTC), Verizon Communications (VZ), Cisco Systems (CSCO) and CVS Health (CVS).

Who are Becton, Dickinson and Company's major shareholders?

Becton, Dickinson and Company's stock is owned by a number of institutional and retail investors. Top institutional investors include Cacti Asset Management LLC (0.07%), Avity Investment Management Inc. (0.06%), Guyasuta Investment Advisors Inc. (0.05%), Pensioenfonds Rail & OV (0.05%), Saratoga Research & Investment Management (0.03%) and Confluence Investment Management LLC (0.03%). Insiders that own company stock include Alexandre Conroy, Betty D Larson, Claire Fraser, David Hickey, James C Lim, Michael David Garrison, Rebecca W Rimel, Rebecca W Rimel, Richard Byrd, Samrat S Khichi, Thomas E Polen Jr, Thomas J Spoerel and Thomas J Spoerel.
View institutional ownership trends
.

How do I buy shares of Becton, Dickinson and Company?

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Becton, Dickinson and Company have any subsidiaries?
The following companies are subsidiares of Becton, Dickinson and Company: Accuri Cytometers, Accuri Cytometers Inc., Alverix Inc, Alverix Inc., Atto Bioscience Inc, BD Holding S. de R.L. de C.V., BD Infection Prevention BV, BD Kiestra BV, BD Kiestra Total Lab Automation, BD Rapid Diagnostic (Suzhou) Co. Ltd., BD San Luis Potosi S.A. de C.V., BD Switzerland Sarl, BD Ventures LLC, BD West Africa Limited, BDX INO LLC, Bard (Thailand) Limited, Bard ASDI Inc., Bard Access Systems Inc., Bard Acquisition Sub Inc., Bard Australia Pty. Limited, Bard Benelux N.V., Bard Brachytherapy Inc., Bard Brasil Indústria e Comércio de Produtos Para a Saúde Ltda., Bard Canada Inc., Bard Chile S.p.A., Bard Czech Republic s.r.o., Bard Devices Inc., Bard Dublin ITC Limited, Bard EMEA Finance Center Sp.z o.o., Bard European Distribution Center N.V., Bard Finance B.V. & Co. KG., Bard Financial Services Ltd., Bard Finland OY, Bard France S.A.S., Bard Global Holdings I LLC, Bard Global Holdings II LLC, Bard Global Holdings III LLC, Bard Healthcare Inc., Bard Healthcare Science (Shanghai) Limited, Bard Hellas S.A., Bard Holding SAS, Bard Holdings Limited, Bard Holdings Netherlands B.V., Bard Hong Kong Limited, Bard IP Holdings Inc., Bard India Healthcare Pvt. Ltd., Bard International Holdings B.V., Bard International Inc., Bard Istanbul Healthcare Limited Company, Bard Korea Ltd., Bard Limited, Bard MRL Acquisition Corp., Bard Malaysia Healthcare Sdn. Bhd., Bard Medica SA, Bard Medical Devices (Beijing) Co. Ltd., Bard Medical R&D (Shanghai) Co. Ltd., Bard Medical SA (Proprietary) Limited, Bard Mexico Realty S. de R.L. de C.V., Bard Norden AB, Bard Norway AS, Bard Pacific Health Care Company Ltd., Bard Peripheral Vascular Inc., Bard Poland Sp. z.o.o., Bard Productos Plasticos e Medicos Ltda., Bard Reynosa S.A. de C.V., Bard S.r.l., Bard Sdn. Bhd., Bard Shannon Limited, Bard Singapore Private Limited, Bard Sourcing Office Singapore Pte. Ltd., Bard Sweden AB, Bard UK Newco Limited, Bard de Espana S.A., Becton Dickinson (Gibraltar) Holdings Ltd., Becton Dickinson (Gibraltar) Limited, Becton Dickinson (Gibraltar) Management Limited, Becton Dickinson (Mauritius) Limited, Becton Dickinson (Pty) Ltd., Becton Dickinson (Thailand) Limited, Becton Dickinson A.G., Becton Dickinson A/S, Becton Dickinson Argentina S.R.L., Becton Dickinson Asia Holdings Ltd., Becton Dickinson Asia Limited, Becton Dickinson Austria GmbH, Becton Dickinson Austria Holdings GmbH, Becton Dickinson B.V., Becton Dickinson B.V. Saudi Limited Company, Becton Dickinson Benelux N.V., Becton Dickinson Biosciences Systems and Reagents Inc., Becton Dickinson Canada Inc., Becton Dickinson Caribe Ltd., Becton Dickinson Croatia d.o.o., Becton Dickinson Czechia s.r.o., Becton Dickinson Dispensing Belgium BVBA, Becton Dickinson Dispensing Denmark A/S, Becton Dickinson Dispensing France SAS, Becton Dickinson Dispensing Ireland Limited, Becton Dickinson Dispensing Norway, Becton Dickinson Dispensing Spain S.L.U., Becton Dickinson Dispensing UK Ltd., Becton Dickinson Distribution Center N.V., Becton Dickinson East Africa Ltd., Becton Dickinson Euro Finance Sarl, Becton Dickinson Europe Holdings S.A.S., Becton Dickinson France S.A.S., Becton Dickinson GSA Beteilgungs GmbH, Becton Dickinson Global Holdings I Inc., Becton Dickinson Global Holdings II LLC, Becton Dickinson Global Holdings IV LLC, Becton Dickinson Global Holdings V LLC, Becton Dickinson Global Holdings VII LLC, Becton Dickinson Global Holdings VIII LLC, Becton Dickinson Global Services Centre Sdn. Bhd, Becton Dickinson GmbH, Becton Dickinson Guatemala S.A., Becton Dickinson Hellas S.A., Becton Dickinson Holdings Limited, Becton Dickinson Holdings Ltd., Becton Dickinson Holdings Pte Ltd., Becton Dickinson Hungary Kft., Becton Dickinson India Private Limited, Becton Dickinson Industrias Cirurgicas Ltda., Becton Dickinson Infusion Therapy AB, Becton Dickinson Infusion Therapy Holdings UK Limited, Becton Dickinson Infusion Therapy Systems Inc., Becton Dickinson Infusion Therapy Systems Inc. S.A. de C.V., Becton Dickinson Infusion Therapy UK, Becton Dickinson Insulin Syringe Ltd., Becton Dickinson International Holdings II Pte Ltd., Becton Dickinson International Holdings III Pte Ltd., Becton Dickinson International Holdings Pte Ltd., Becton Dickinson Israel Ltd., Becton Dickinson Italia S.p.A., Becton Dickinson Ithalat Ihracat Limited Sirketi, Becton Dickinson Korea Holding Inc., Becton Dickinson Korea Ltd., Becton Dickinson Ltd., Becton Dickinson Luxembourg Finance S.a.r.L., Becton Dickinson Luxembourg Global Holdings Sarl, Becton Dickinson Luxembourg Holdings II S.a.r.L, Becton Dickinson Luxembourg Holdings III S.a.r.L, Becton Dickinson Luxembourg Holdings V S.a.r.L., Becton Dickinson Malaysia Inc., Becton Dickinson Management GmbH & Co. KG, Becton Dickinson Matrex Holdings Inc., Becton Dickinson Medical (S) Pte Ltd., Becton Dickinson Medical Devices (Shanghai) Co. Ltd., Becton Dickinson Medical Devices (Suzhou) Co. Ltd., Becton Dickinson Medical Products Pte. Ltd., Becton Dickinson Medical Technology (Jiangsu) Co. Ltd., Becton Dickinson Netherlands Global Holdings II C.V., Becton Dickinson Netherlands Holdings B.V., Becton Dickinson Netherlands Holdings II B.V., Becton Dickinson Norway AS, Becton Dickinson O.Y., Becton Dickinson Overseas Services Ltd., Becton Dickinson Pakistan (Pvt) Ltd., Becton Dickinson Penel Limited, Becton Dickinson Philippines Inc., Becton Dickinson Polska Sp.z.o.o., Becton Dickinson Portugal Unipessoal Lda., Becton Dickinson Pty. Ltd., Becton Dickinson Research Centre Ireland Limited, Becton Dickinson Rowa Germany GmbH, Becton Dickinson Rowa Italy Srl, Becton Dickinson S.A., Becton Dickinson Sample Collection GmbH, Becton Dickinson Scot Financing L.L.P., Becton Dickinson Scot Financing L.P., Becton Dickinson Sdn. Bhd., Becton Dickinson Slovakia s.r.o., Becton Dickinson Sweden AB, Becton Dickinson Sweden Holdings AB, Becton Dickinson Switzerland Global Holdings SarL, Becton Dickinson Technology Campus India, Becton Dickinson U.K. Limited, Becton Dickinson UK Financing I Limited, Becton Dickinson UK Financing II Limited, Becton Dickinson Venezuela C.A., Becton Dickinson Venture LLC, Becton Dickinson Verwaltungs GmbH, Becton Dickinson Vostok LLC, Becton Dickinson Worldwide Investments Sa.r.L., Becton Dickinson Zambia Limited, Becton Dickinson and Company Ltd., Becton Dickinson de Colombia Ltda., Becton Dickinson de Mexico S.A. de C.V., Becton Dickinson del Uruguay S.A., Bee IT Solutions, Benex Ltd., Biometric Imaging, Bridger Biomed Inc., C. R. Bard (Portugal) - Produtos e Artigos Medicos e Farmaceuticos, C. R. Bard Do Brasil Productos Medicos Ltda., C. R. Bard GmbH, C. R. Bard Inc., C. R. Bard Netherlands Sales B.V., C.R. Bard Inc, CME America LLC, CME Ltd., CME Medical (UK) Limited, CME UK (Holdings) Limited, CRISI Medical Systems, CRISI Medical Systems Inc., Caesarea Medical Electronics, Cardal II LLC, Care Fusion Development Private Limited, CareFusion (Barbados) SrL, CareFusion (Shanghai) Commercial and Trading Co. Limited, CareFusion 213 LLC, CareFusion 2200 Inc., CareFusion 2201 Inc., CareFusion 302 LLC, CareFusion 303 Inc., CareFusion Asia (HK) Limited, CareFusion Corporation, CareFusion Corporation., CareFusion D.R. 203 Ltd., CareFusion France 309 S.A.S., CareFusion Israel 330 Ltd., CareFusion Italy 312 S.p.A., CareFusion Manufacturing LLC, CareFusion Mexico 215 S.A. de C.V., CareFusion Netherlands 328 B.V., CareFusion Netherlands 503 B.V., CareFusion Netherlands 504 B.V., CareFusion Netherlands Financing 283 C.V., CareFusion Resources LLC, CareFusion S.A. 319 (Proprietary) Limited, CareFusion Solutions LLC, CareFusion U.K. 244 Limited, CareFusion U.K. 305 Limited, CareFusion U.K. 306 Limited, Carmel Pharma AB, Carmel Pharma Inc, Cato Software Solutions, Cell Analysis Systems Inc, Cellular Research, Cellular Research Inc., Clearstream Technologies Group Limited, Clearstream Technologies Limited, Clontech Laboratories Inc, Corporativo BD de Mexico S. de R.L. de C.V., Critical Device Corporation, Cubex, Cytognos, Cytopeia Inc, DLD (Bermuda) Ltd., DVL Acquisition Sub Inc., Davol Inc., Davol International Limited, Davol Surgical Innovations S.A. de C.V., Difco Laboratories Incorporated, Distribuidora BD Mexico S.A. de C.V., Dutch American Manufacturers (D.A.M.) B.V., Dymax Corporation, Embo Medical Limited, Enturia de Mexico S. de R.L. de C.V., Enturican Inc., FJ International Inc., FlowCardia Inc., FlowCardia LLC, FlowJo LLC, Franklin Lakes Enterprises L.L.C., GSL Solutions, Gamer Lasertechnik GmbH, GenCell Biosystems, GenCell Biosystems Ltd., GeneOhm Sciences Canada ULC, GeneOhm Sciences Inc, Gentest Corporation, Gesco International Inc., Gesco International LLC, Glentech Inc, HandyLab Inc, HandyLab Inc., IBD Holdings LLC, Iontophoretics Corporation, JoHome LLC, Kabushiki Kaisha Medicon (Medicon Inc.), Liberator Health and Education Services Inc., Liberator Health and Wellness Inc., Liberator Medical Holdings Inc., Liberator Medical Supply Inc., Limited Liability Company Bard Rus, Loma Vista Medical Inc., Loma Vista Medical LLC, Luther Medical Products Inc, Lutonix Inc., Med-Design Corporation, Med-Design Investment Holdings Inc., Med-Safe Systems Inc, Med-Safe Systems Inc., MedChem Products Inc., Medafor Inc., Medegen LLC, Medinservice.com Inc., Medivance Inc., NAT Diagnostics Inc., NAT Diagnostics Inc., NOW Medical Distribution Inc., NOW Medical Distribution LLC, Navarre Biomedical LLC, Navarre Biomedical Ltd., Neomend Inc., Nippon Becton Dickinson Company Ltd., Omega Biosystems Incorporated, P.R.C. (Isialys) Societe a responsabilitie limitee, PT Becton Dickinson Indonesia, PharMingen, PharMingen., Plasso Technology Ltd, PreAnalytiX GmbH, Pristine Access Technologies Inc., ProSeed Inc., Procesos para Esterilizacion S.A. de C.V., Productos Bard de Mexico S.A. de C.V., Productos Para el Cuidado de la Salud S.A. de C.V., Puls Medical Devices AS LC, PureWick Corporation, Roberts Laboratories Inc., Rochester Medical Corporation, Rochester Medical Ltd., Saf-T-Med Inc, Safety Syringes Inc., Scanwell Health Inc., Sendal S.L.U., SenoRx Inc., SenoRx LLC, Shield Healthcare Centers Inc., Sirigen Group Limited, Sirigen II Limited, Sirigen Inc., Sistemas Médicos ALARIS S.A. de C.V., Specialized Cooperative Corporation, Specialized Health Products Inc., Specialized Health Products International Inc., Specialized Health Products International LLC, Staged Diabetes Management LLC, Straub Medical AG, Straub Medical AG, Surgical Site Solutions Inc., TVA Medical Inc, TVA Medical Inc., Tepha Inc, Tepha Inc., Tissuemed Ltd., Tri-County Medical & Ostomy Supplies Inc., TriPath Imaging Inc., Tru-Fit Marketing Corporation, Vas-Cath Incorporated, Vascular Pathways Inc., Velano Vascular, Velano Vascular Inc., Venclose Inc., Venetec International Inc., Venetec International LLC, Visitec, Y-Med Inc., Y-Med LLC, and ZebraSci Inc..
Read More
This page (NYSE:BDX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners